Pityriasis rosea-like eruption during treatment with imatinib mesylate: Description of 3 cases

被引:38
作者
Brazzelli, V
Prestinari, F
Roveda, E
Barbagallo, T
Bellani, E
Vassallo, C
Orlandi, E
Passamonti, F
Borroni, G
机构
[1] Univ Pavia, IRCCS, Policlin San Matteo, Dept Human & Hereditary Pathol,Inst Dermatol, I-27100 Pavia, Italy
[2] Univ Pavia, IRCCS, Policlin San Matteo, Inst Hematol, I-27100 Pavia, Italy
关键词
D O I
10.1016/j.jaad.2004.10.888
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Imatinib mesylate (IM) represents the first-line treatment for chronic myeloid leukemia (CML). We hereby relate 3 cases of in IM-induced pityriasis rosea (PIZ)-like cutaneous eruption. Patients developed In erythematous slightly pruritic, macular skin eruption, with many lesions having a peripheral collarette of desquamation, confined to the trunk, limbs, and arms with a vaguely dermatomal diffusion. The histologic findings suggested a reactive process to the drug. Full dermatological recovery was obtained after IM discontinuation, but lesions, reappeared upon restoring therapy, suggesting the drug-related nature of the rash. To our knowledge this is the first reported PR-like cutaneous eruption to IM.
引用
收藏
页码:S240 / S243
页数:4
相关论文
共 23 条
[1]  
ACKERMAN AB, 1997, HISTOLOGIC DIAGNOSIS, P623
[2]   Cutaneous reactions to STI571 [J].
Brouard, M ;
Saurat, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (08) :618-619
[3]   Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia [J].
Brouard, MC ;
Prins, C ;
Mach-Pascual, S ;
Saurat, JH .
DERMATOLOGY, 2001, 203 (01) :57-59
[4]  
BUCKLEY C, 1996, BRIT J DERMATOL, V135, P652
[5]   Human herpesvirus 6 and 7 DNA in peripheral blood leucocytes and plasma in patients with pityriasis rosea by polymerase chain reaction: A prospective case control study [J].
Chuh, AAT ;
Chiu, SSS ;
Peiris, JSM .
ACTA DERMATO-VENEREOLOGICA, 2001, 81 (04) :289-290
[6]   Mycosis fungoides-like reaction in a patient treated with Gleevec [J].
Clark, SH ;
Duvic, M ;
Prietol, VG .
JOURNAL OF CUTANEOUS PATHOLOGY, 2003, 30 (04) :279-281
[7]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[8]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[9]   Mechanisms of disease - The biology of chronic myeloid leukemia [J].
Faderl, S ;
Talpaz, M ;
Estrov, Z ;
O'Brien, S ;
Kurzrock, R ;
Kantarjian, HM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (03) :164-172
[10]  
Hasan S, 2003, J NATL MED ASSOC, V95, P722